

NCI–ASCO Cancer Trial Accrual Symposium: Science and Solutions
BREAKOUT SESSIONS

7 Breakout sessions (1.5 hours each) divided into 3 tracks (each given twice for a total of 14):

- I. Patient/Participant-Centered Solutions (3 topics)
- II. Physician/Provider-Centered Solutions (2 topics)
- III. Site/System-Centered Solutions (2 topics)

Track 1: Patient/Participant-Centered Solutions (Interventions targeted at helping patients and communities better understand and access trials)

1.1 The Science of Patient Participation, Decision Making and Informed Consent

- Patient education/decision making and informed consent (issues specific to minority and underserved populations will be addressed in a separate breakout)
- Consider differences across phases of trials and types of trials including prevention, treatment, symptom management, and biomarker studies

Session 1.1 Co-Leaders:

- ❖ Peggy Devine, B.S., CLS (Steering Committee Member) — Cancer Information and Support Network
- ❖ Afshin Dowlati, M.D. — Case Western Reserve University
- ❖ Kevin Weinfurt, Ph.D. (Steering Committee Member) — Duke Clinical Research Institute — Session Chair

1.2 The Science of Minority and Underrepresented Population Accrual

- Decision making and informed consent of minority and underserved populations, including interventions that promote trust in cancer care
- Integrating cultural issues in patient education

Session 1.2 Co-Leaders:

- ❖ Jean Ford, M.D. (Steering Committee Member) — Johns Hopkins Bloomberg School of Public Health
- ❖ Derek Raghavan, M.D., Ph.D. — Cleveland Clinic — Session Chair
- ❖ Steven Wolff, M.D., FACP — Meharry Medical College

1.3 The Science of Community Outreach, Education, and Participation

- Community education and awareness of clinical trials, including social marketing interventions and disease registries for patients
- The role of Community Organizations, Community Advisory Boards (CABs) and Community-Based Participatory Research principles in promoting trial accrual

Session 1.3 Co-Leaders:

- ❖ Mona Fouad, M.D., M.P.H. — University of Alabama School of Medicine
- ❖ William J. Hicks M.D. — The Ohio State University Medical Center and Richard J. Solove Research Institute
- ❖ Margo Michaels, M.P.H. — Education Network to Advance Cancer Clinical Trials — Session Chair

Track 2: Physician and Provider-Centered Solutions (Interventions targeted at improving physician/provider communication and planning for clinical trials)

2.1 The Science of Physician/Provider Communication With Participants and Colleagues

- Communicating risk/benefit and equipoise in trials
- Integrating trials as a cancer treatment and prevention option
- Assessing patient/family receptiveness and readiness for trial discussion
- Educating and communicating with colleagues about trials

Session 2.1 Co-Leaders:

- ❖ Terrance Albrecht, Ph.D. — Barbara Ann Karmanos Cancer Institute
- ❖ Michelle E. Duff, D.P.T. — Director of Research and Scientific Affairs, Pancreatic Cancer Action Network
- ❖ Lidia Schapira, M.D. (Steering Committee Member) — Harvard Medical School, Massachusetts General Hospital – Session Chair

2.2 The Science of Recruitment Planning and Evaluation

- Establishing recruitment plans and recruitment methodology
- Developing and standardizing accrual metrics, including terminology and reporting outcomes
- Establishing and using disease registries for patient recruitment

Session 2.2 Co-Leaders:

- ❖ Marge Good, R.N., M.P.H., B.S.N., OCN — Wichita Community Clinical Oncology Program
- ❖ Ellen Richmond, M.S., R.N. — National Cancer Institute — Session Chair
- ❖ Debra Wujcik, Ph.D., R.N. — Vanderbilt University

Track 3: Site Leadership, Infrastructure and Operations (Strategies optimizing site leadership and operations to better select and support trials to reach accrual goals)

3.1 The Science of Effective Leadership and Organizational Culture to Promote Accrual

- Effective trial leadership and creation of an organizational culture that fosters and supports clinical research

Session 3.1 Co-Leaders:

- ❖ Robert Comis, M.D. (Steering Committee Member) — Coalition of Cancer Cooperative Groups, Eastern Cooperative Oncology Group
- ❖ Patrick Loehrer, M.D. — Indiana University School of Medicine
- ❖ Robin Zon, M.D., FACP — Michiana Hematology Oncology — Session Chair

3.2 The Science of Trial Selection, Infrastructure, and Operations

- Creating systems that allow for more streamlined operations, efficient clinical research support offices/infrastructure, and staffing levels required to achieve research goals
- Decision making about planning, prioritizing, resourcing and selecting trials

Session 3.2 Co-Leaders:

- ❖ Michael Bookman, M.D. — Arizona Cancer Center
- ❖ David Dilts, Ph.D., M.B.A. (Steering Committee Member) — Oregon Health and Science University — Session Chair
- ❖ Alan Lyss, M.D. — Heartland Cancer Research Community Clinical Oncology Program, Missouri Baptist Cancer Center